^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Simponi (golimumab)
i
Other names: CNTO148, CNTO 148, CNTO-148
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
J&J, Merck (MSD), Tanabe Pharma
Drug class:
TNFα inhibitor
Related drugs:
8d
Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study (clinicaltrials.gov)
P2, N=8, Active, not recruiting, University of Washington | Trial completion date: Apr 2026 --> Apr 2027
Trial completion date
|
apalutamide • Simponi (golimumab)
24d
PRIMERA001: Comparing the effectiveness of our tailor-made management approach with routine care from a clinical, patient's as well as an economic point of view. Tailoring of treatment is done by taking the presence of autoantibodies and the quick response to glucocorticoids and JAK inhibitors into account. (2024-511530-12-01)
P4, N=300, Active, not recruiting, Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) | Not yet recruiting --> Active, not recruiting
Enrollment closed
|
hydroxychloroquine • Simponi (golimumab) • leflunomide • methylprednisolone acetate
25d
Efficacy of Different Biological Treatments in Patients With Inflammatory Bowel Disease After One Year of Treatment in Upper Egypt (clinicaltrials.gov)
P=N/A, N=95, Not yet recruiting, Assiut University
New trial
|
Entyvio (vedolizumab) • Simponi (golimumab)
1m
Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study (clinicaltrials.gov)
P2, N=8, Active, not recruiting, University of Washington | Recruiting --> Active, not recruiting | N=34 --> 8 | Trial completion date: Dec 2027 --> Apr 2026 | Trial primary completion date: Mar 2027 --> Jul 2025
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
|
apalutamide • Simponi (golimumab)
2ms
Current and Emerging Therapies for Uveitis in Axial Spondyloarthritis: A Scoping Review. (PubMed, Mediterr J Rheumatol)
Uveitis exposure-adjusted incidence rates per 100 patient years (EAIR/100PY) ranged between 0-4.5 for tumour necrosis factor inhibitors (TNFi), 0.5-3.9 for interleukin-17 inhibitors (IL-17i) and 0.8-3.3 for upadacitinib (UPA), as derived from available RCTs. Evidence from non-RCTs, reporting uveitis incidence rates per 100PY, ranged between 3.46-55.2 for etanercept, 1.38-15.7 for adalimumab, 1.82-25.9 for infliximab, 1.39-6.8 for golimumab, 0-9.4 for secukinumab and 0 for ixekizumab...IL-17i are identified as second line treatment option especially in uveitis refractory to TNFi. Finally, JAKi remain a promising alternative, with more evidence needed to further establish their so far proven efficacy.
Review • Journal
|
IL17A (Interleukin 17A)
|
Cosentyx (secukinumab) • Simponi (golimumab)
3ms
Clinical Features and Outcome of Patients With Juvenile Spondyloarthropathy in a Tertiary Hospital in the Philippines. (PubMed, Clin Pediatr (Phila))
The JSpA in this cohort demonstrated substantial disease burden, with frequent axial and peripheral involvement. Although 43.2% of patients achieved clinical remission, sustained remission off medication was observed in only 10.2%, reflecting the chronic disease course. Early diagnosis and optimized treatment strategies remain essential to improve outcomes.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha)
|
Simponi (golimumab)
3ms
Recent advances in biologic therapies for ankylosing spondylitis: A 2024 update. (PubMed, Allergol Immunopathol (Madr))
This comprehensive analysis assesses therapeutic outcomes and adverse effects of TNFi, IL17i, and JAKi in AS care.
Review • Journal
|
IL17A (Interleukin 17A)
|
tofacitinib • Cosentyx (secukinumab) • Simponi (golimumab)
4ms
Evaluation of the placebo and treatment effect overtime in randomised clinical trials evaluating the efficacy of biologics in axial spondyloarthritis: systematic review and meta-analysis. (PubMed, Ann Rheum Dis)
ASAS20/40 treatment effects have declined over time in axSpA trials, consistent with a fading of reported effectiveness, whereas ASDAS-based endpoints remain stable, indicating greater robustness to placebo effects and temporal trends.
Retrospective data • Journal
|
IL17A (Interleukin 17A) • CRP (C-reactive protein)
|
Cosentyx (secukinumab) • Simponi (golimumab)
4ms
Rate and predictors of successful antitumor necrosis factor deescalation after dose intensification in inflammatory bowel disease patients: a real-world Greek-Turkish collaborative study. (PubMed, Eur J Gastroenterol Hepatol)
One quarter of IBD patients requiring intensified anti-TNFa therapie were successfully deescalated to standard dosing, after a median of 16.0 (IQR: 8.0-36.0) months.
Journal • Real-world evidence
|
TNFA (Tumor Necrosis Factor-Alpha)
|
Simponi (golimumab)
5ms
Lucentis Plus Tagolimumab in PD-L1+, HR+/HER2- Advanced Breast Cancer After CDK4/6 Inhibitors (clinicaltrials.gov)
P2, N=35, Not yet recruiting, Sun Yat-sen University
New P2 trial
|
PD-L1 (Programmed death ligand 1)
|
Lucentis (ranibizumab) • Simponi (golimumab)
5ms
EFFECT-1LAT: Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population (clinicaltrials.gov)
P=N/A, N=4000, Not yet recruiting, Pfizer | Trial completion date: Oct 2025 --> Mar 2026 | Initiation date: Sep 2025 --> Dec 2025 | Trial primary completion date: Oct 2025 --> Mar 2026
Trial completion date • Trial initiation date • Trial primary completion date
|
tofacitinib • Entyvio (vedolizumab) • Simponi (golimumab)
6ms
EVOLUTION: Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients (clinicaltrials.gov)
P3, N=63, Recruiting, University of Pennsylvania | N=150 --> 63 | Trial completion date: May 2026 --> Oct 2026 | Trial primary completion date: May 2026 --> Oct 2026
Enrollment change • Trial completion date • Trial primary completion date
|
Simponi (golimumab)
Share via
